Simcere Pharmaceutical Group Provides Notice of Annual General Meeting

NANJING, China, July 14 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced that the annual general meeting of shareholders (the "Meeting") will be held on Wednesday, July 28, 2010 at 10 a.m. Beijing time, at No.699-18, Xuanwu Avenue, Xuanwu District, Nanjing, People's Republic of China.

The meeting is being held for the following purposes:

1. To receive a report on the Company's operation;

2. To transact any other business properly brought before the Meeting.

All shareholders of record at the close of business on July 16, 2010 will be entitled to attend and vote at the Meeting, and at any adjournment or postponement thereof, or to appoint a proxy to attend and vote in his/her place. The proxy need not be a shareholder of the Company.

This notice and other information with regards to the Meeting are available on the investor relation section of the Company's website: http://www.simcere.com .

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

For more information, please contact:

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:

Frank Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556-6666 x8818

In Beijing:

Ruirui Jiang

Brunswick Group

Tel: +86-10-6566-2256

In the United States:

Kate Tellier

Brunswick Group

Tel: +1-212-333-3810

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852-3512-5000

Related stocks: NYSE:SCR